Chronic Myeloid Leukemia

Emerging Therapies in CML Undergo Investigation in Chronic-Phase Illness

October 07, 2020

Today’s patients diagnosed with chronic myeloid leukemia can look forward to a near-normal life expectancy, provided they have good access to treatment and monitoring and are properly managed, said Jorge Cortes, MD.

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

PFS and EFS Extended With Ibrutinib Monotherapy in Early-Stage CLL

June 18, 2019

Patients with early-stage, asymptomatic, newly diagnosed chronic lymphocytic leukemia showed improved survival outcomes with ibrutinib monotherapy compared with placebo, according to results from phase III CLL12 study presented at the 2019 European Hematology Association Congress.

Acalabrutinib Plus Obinutuzumab Prompts High Response Rate in Patients with CLL

June 05, 2019

Patients with chronic lymphocytic leukemia showed high responses when given a combination of acalabrutinib and obinutuzumab, which targets BTK and the CD20 antigen. High response rates over 90% were seen across various settings of disease, according to the results of a small, preliminary trial.

Venetoclax/Obinutuzumab Combo Advances PFS in Previously Untreated CLL

June 05, 2019

According to the pivotal phase III CLL14 study presented during the 2019 American Society of Clinical Oncology Annual Meeting, venetoclax plus obinutuzumab demonstrated a lengthening in progression-free survival time for patients with previously untreated chronic lymphocytic leukemia compared with obinutuzumab plus chlorambucil. Trial results show that the chemotherapy-free combination reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil.